

Edgar Filing: VIRAGEN INC - Form 424B2

VIRAGEN INC  
Form 424B2  
August 09, 2001

1

Filing Pursuant to Rule 424(b)(2)  
Registration Statement No. 333-32306

PROSPECTUS SUPPLEMENT  
(TO PROSPECTUS DATED MARCH 21, 2000)

172,062 shares

Viragen, Inc.

Common Stock

-----

You should read this prospectus supplement and the related prospectus carefully before you invest. Both documents contain information you should consider when making your investment decision.

INVESTING IN VIRAGEN, INC. COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. SEE "RISK FACTORS" BEGINNING ON PAGE 6 OF OUR PROSPECTUS DATED MARCH 21, 2000 TO READ ABOUT FACTORS YOU SHOULD CONSIDER BEFORE BUYING SHARES OF OUR COMMON STOCK.

PLAN OF DISTRIBUTION

We are offering 160,806 shares of our common stock to Ladenburg Thalmann & Co. Inc. under the terms of this prospectus supplement. The common stock will be purchased at a negotiated purchase price of \$225,000. In addition, we will pay \$4,500 in commissions on the sale of our common stock to Thomas Systems, Inc., as the finder in connection with this transaction. We will also issue Ladenburg Thalmann a three (3) year warrant to purchase 11,256 shares of our common stock at an exercise price per share of \$1.81. We expect this transaction to close following this filing. We will not pay any other compensation in conjunction with this sale of our common stock in addition to the arrangements discussed in our prospectus dated March 21, 2000. We have agreed to indemnify the placement agent against liabilities, including liabilities under the Securities Act of 1933.

USE OF PROCEEDS

The net proceeds to us from this offering will be \$220,500. We plan to use the net proceeds for general corporate purposes, including:

2

- o funding of clinical trials of our Omniferon(TM) product;
- o funding collaborative research projects for the development of new technologies;
- o financing capital expenditures; and
- o working capital.

Pending use of the net proceeds for any of these purposes, we may

## Edgar Filing: VIRAGEN INC - Form 424B2

invest the net proceeds in short-term investment grade instruments, interest-bearing bank accounts, certificates of deposit, money market securities, U.S. government securities or mortgage-backed securities guaranteed by federal agencies.

### MARKET FOR OUR COMMON STOCK

On August 8, 2001, the last reported sales price of our common shares on the American Stock Exchange was \$1.52 per share. Our common stock began trading under the symbol "VRA" on April 17, 2000, on the American Stock Exchange.

As of August 8, 2001 and before the issuance of shares pursuant to this prospectus supplement, we had 99,483,897 shares of common stock outstanding.

### GENERAL

You should rely only on the information provided or incorporated by reference in this prospectus supplement and the prospectus. We have not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date on the front of these documents.

### DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

The statements contained in this supplemental prospectus that are not purely historical are forward-looking statements within in the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. These include statements regarding Viragen's expectations, hopes, intentions, beliefs, or strategies regarding the future. Forward-looking statements include our statements regarding liquidity, anticipated cash needs and availability, and anticipated expense levels, including expected product clinical trial commencement dates, product introductions, expected research and development expenditures and related anticipated costs. All forward-looking statements included in this document or documents incorporated by reference are based on information available on this date, and we assume no obligation to update any of our forward-looking statements. You should note that actual results could differ materially from those contained in forward-looking statements. Among the factors that may cause our actual results to differ materially are the risks discussed in the "Risk Factors" section included in the related prospectus.

-----

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY OTHER REGULATORY BODY HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THE RELATED PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

-----

The date of this prospectus supplement is August 9, 2001.

### TABLE OF CONTENTS

PAGE  
----

Edgar Filing: VIRAGEN INC - Form 424B2

PROSPECTUS SUPPLEMENT

Plan of Distribution .....	1
Use of Proceeds.....	1
Market for our Common Stock .....	2
General .....	2
Disclosure Regarding Forward-Looking Statements.....	2